Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2021 Financial Results on February 15, 2022
24 janv. 2022 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Announces Preliminary, Unaudited 2021 Revenue Results and CFO Transition
10 janv. 2022 08h30 HE
|
Adaptive Biotechnologies
SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) today reported preliminary, unaudited revenue for the year ended December 31, 2021. Total revenue for...
Updated: Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
29 déc. 2021 08h00 HE
|
Adaptive Biotechnologies
SEATTLE, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting
13 déc. 2021 16h05 HE
|
Adaptive Biotechnologies
Analysis of the MASTER trial (Abstract 481) showed clonoSEQ’s ability to measure deep and durable responses and permit treatment discontinuation in multiple myeloma patientsData in more than 30...
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts on Utility of clonoSEQ® in MRD Testing in Blood Cancer Patients at the 63rd ASH Annual Meeting
02 déc. 2021 08h00 HE
|
Adaptive Biotechnologies
SEATTLE, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients
11 nov. 2021 17h52 HE
|
Adaptive Biotechnologies
Local coverage determination (LCD) confirms access to the only FDA-cleared in vitro diagnostic to detect and monitor minimal residual disease (MRD) from bone marrow and blood sample types in certain...
Adaptive Biotechnologies Reports Third Quarter 2021 Financial Results
03 nov. 2021 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 3, 2021
06 oct. 2021 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating the Capability of Its Immune Medicine Platform to Distinguish Between SARS-CoV-2 Infection and Vaccine Response and Detect Lyme Disease
02 oct. 2021 13h15 HE
|
Adaptive Biotechnologies
Real-world data show T-Detect™ COVID can detect prior SARS-CoV-2 infection nearly 12 months after initial diagnosis in some patients New research demonstrates T-cell testing using T-cell receptor...